CAREDX INITIATES COMPULSORY ACQUISITION PROCEEDINGS AND ALLENEX FILES FOR DE-LISTING

CareDx, Inc ("CareDx") announced on 8 April 2016 that the company completes its
public offer to the shareholders of Allenex AB (publ), ("Allenex"). After
completion of the offer, CareDx holds approximately 98.3 percent of the shares
of Allenex and has notified Allenex’ board of directors that CareDx has resolved
to initiate compulsory acquisition proceedings regarding the remaining shares.

In light of the above, Allenex’ board of directors does not consider it
motivated for Allenex to remain a listed company and has therefore decided to
apply for de-listing of the Allenex share from Nasdaq Stockholm. The last day of
trading in the Allenex share will be announced as soon as a notification thereof
has been received from Nasdaq Stockholm.

For more information please contact:
Anders Karlsson, CEO Allenex AB, and ph.: +4670-918 00 10, e-mail:
anders.karlsson@allenex.se

Allenex AB discloses the information provided herein pursuant to the Securities
Markets Act and /or the Financial Instruments Trading Act. The information was
submitted for publication on May 20, 2016, at 08:00 CET.  Allenex is a life
science-company that develops, manufacture, market and sell products for safer
transplants of organs and bone marrow on the global market. Allenex is listed on
NASDAQ OMX Stockholm Small Cap (ticker: ALNX). 57 persons are employed in the
Allenex group.